Rossari Biotech543213Specialty chemicals
Rossari Biotech reported strong quarter two earnings driven by higher exports and improved margins, even as the stock fell 3.5 percent despite the good numbers
By ScoutQuest · · 1 min read
- Export revenue last quarter
- 221 crore rupees
- H1 EBITDA and revenue growth
- more than 20 percent
- Cash flow generated
- 131 crore rupees
- Stock move today
- down 3.5 percent
Heard on business television between 12:09:51 - 12:12:51 IST.
- Co-founder and MD Sunil Chari said exports were strong at ₹221 crore last quarter, boosting margins
- First half saw over 20% growth in both EBITDA and top line
- PAT impacted by higher depreciation and higher finance costs
- Company generated strong cash flows of ₹131 crore and reduced working capital days
- Management focusing on capital preservation and improving ROCE and ROE through higher asset utilization and lower finance costs going forward
- Stock fell 3.5% despite the good results, in line with broader weakness in chemical stocks
Watch at source
behind live
- 1Open on YouTube
- 2Drag the seek bar left
- 3Watch this moment
Also from Rossari Biotech
Earnings call: record quarterly revenue and EBITDA; Board approves land lease for Saudi greenfield plant
23 Oct 2026
Rossari Biotech files audio recording of Q2 & H1 FY27 earnings conference call held October 19, 2026
19 Oct 2026
Rossari Biotech stock up 21% as net profit rose 5% and export sales jumped, in line with street expectations of strong numbers
19 Oct 2026
Source: Live TV News Channel · 19 Oct 2026
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.